Skip to main content

Table 1 Demographic and clinical characteristics of resected pancreatic cancer patients1

From: Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study

Variable Category The US Belgium The Netherlands Slovenia Norway
Incidence (per 100,000)2 Male 8.6 7.4 7.4 9.3 7.8
Female 6.5 5.6 6.1 6.5 6.5
Years of diagnosis   2004–2015 2004–2013 2003–2014 2003–2013 2003–2014
n   9519 1105 982 118 113
Diagnosis in 2010 or later Yes 5635 (59) 579 (52) 747 (76) 67 (57) 79 (70)
Sex Female 4671 (49) 522 (47) 483 (49) 50 (42) 58 (51)
Age (years) Median (interquartile range) 65 (58–72) 65 (58–71) 64 (57–69) 61 (54–68) 63 (59–70)
Mean ± standard deviation 65 ± 10 64 ± 10 62 ± 9 61 ± 9 64 ± 8
< 50 706 (7) 90 (8) 92 (9) 11 (9) 4 (4)
50–59 2101 (22) 264 (24) 235 (24) 38 (32) 29 (26)
60–69 3464 (36) 406 (37) 417 (42) 46 (39) 50 (44)
≥ 70 3248 (34) 345 (31) 238 (24) 23 (19) 30 (27)
Tumor location3 Pancreas head 7314 (83) 658 (82) 820 (90) 97 (92) 91 (88)
Pancreas body 622 (7) 58 (7) 31 (3) 5 (5) 4 (4)
Pancreas tail 845 (10) 86 (11) 63 (7) 3 (3) 8 (8)
Other 738 (8) 303 (27) 68 (7) 13 (11) 10 (9)
T stage4 T1 494 (5) 56 (5) 72 (7) 0 (0) 8 (8)
T2 1192 (13) 185 (17) 182 (19) 8 (7) 28 (26)
T3 7815 (82) 860 (78) 727 (74) 108 (93) 70 (66)
N stage5 N1 6339 (67) 805 (73) 703 (72) 97 (84) 60 (55)
Differentiation6 Well 858 (10) 149 (15) 91 (11) 12 (11) 3 (3)
Intermediate 4540 (52) 511 (52) 423 (51) 44 (40) 64 (63)
Poor/undifferentiated 3266 (38) 326 (33) 319 (38) 55 (50) 35 (34)
  1. 1Categorical data are shown as count (percentage [%]). For brevity, results for the counterparts in dichotomous variables are omitted. Records are complete otherwise specified below
  2. 2The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World (WHO 2000–2025) Standard Population
  3. 3The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total tumor cases of the four locations; “other” includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases
  4. 4Missing T stage: the US: 18 (< 1%); Belgium: 4 (< 1%); the Netherlands: 1 (< 1%); Slovenia: 2 (2%); Norway: 7 (6%)
  5. 5Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%)
  6. 6Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%)